Drug intelligence / Profile preview

DWJ1543 + DWC202307

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Combination of two investigational small molecule drugs, **DWJ1543** and **DWC202307**, both developed by Daewoong Pharmaceutical. Currently, this combination is being studied for its safety and pharmacokinetics in healthy adult volunteers. The available evidence centers on randomized, open-label, two-way crossover, phase 1 trials, where the combination is administered orally. The mechanism of action, detailed therapeutic targets, and primary indications beyond pharmacokinetic characterization have not been disclosed.

Beyond the preview

Go deeper on DWJ1543 + DWC202307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1543 + DWC202307.

Explore the full profile